Cyclacel Pharmaceuticals, Inc. (CYCC)
NASDAQ: CYCC · IEX Real-Time Price · USD
2.025
+0.025 (1.25%)
Mar 28, 2024, 10:37 AM EDT - Market open

Cyclacel Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017201620152014 2013 - 2001
Net Income
-22.76-21.4-18.66-12.42-8.03-7.49-14.85-11.99-14.54-19.59
Upgrade
Depreciation & Amortization
0.030.030.040.020.020.030.030.130.210.17
Upgrade
Share-Based Compensation
1.471.511.160.430.470.330.270.780.751.22
Upgrade
Other Operating Activities
4.94-1.17-1.280.06-2.10.23-0.310.8-1.07-0.71
Upgrade
Operating Cash Flow
-16.11-20.83-18.54-7.93-9.45-6.7-7.48-10.08-14.46-18.7
Upgrade
Capital Expenditures
-0.01-0.01-0.03-0.10.03-0.04-0.010.01-0.03-0.31
Upgrade
Other Investing Activities
--------0.10.38
Upgrade
Investing Cash Flow
-0.01-0.01-0.03-0.10.03-0.04-0.010.010.060.08
Upgrade
Share Issuance / Repurchase
1.053.221.9429.714.050.6314.956.7911.0612.4
Upgrade
Other Financing Activities
-0.2-0.2-0.2-0.2-0.2-0.2-0.2-0.2-0.2-0.2
Upgrade
Financing Cash Flow
0.85321.7429.53.850.4314.756.5910.8612.2
Upgrade
Exchange Rate Effect
0.3-0.38-0.020.05-0.05-0.10.14-0.44-0.21-0.53
Upgrade
Net Cash Flow
-14.97-18.213.1521.52-5.62-6.417.39-3.92-3.75-6.96
Upgrade
Free Cash Flow
-16.12-20.83-18.57-8.03-9.42-6.74-7.49-10.07-14.49-19.01
Upgrade
Free Cash Flow Margin
-3837.62%-----4493.33%--1194.54%-745.58%-1096.37%
Upgrade
Free Cash Flow Per Share
-19.12-27.77-31.20-33.15-173.13-167.19-294.57-882.05-1602.67-3117.21
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).